Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...

Neuphoria Therapeutics said it expects to receive a milestone payment from Merck for the second clinical trial phase of its Alzheimer's disease dementia treatment.

Co's stock has reached a 52-week low, dipping to $85.71. This downturn reflects a significant shift from the previous year, with the pharmaceutical giant experiencing a 1-year change of -31.59%.

The Senate cleared a procedural hurdle Wednesday to approve Robert F. Kennedy Jr. as Health and Human Services ...